These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20369717)

  • 1. [Calcium-phosphate disturbances in dialysed children and adolescents--one centre analysis between 1991-2008].
    Jander A; Kałuzyńska A; Tkaczyk M
    Pol Merkur Lekarski; 2010 Jan; 28(163):18-21. PubMed ID: 20369717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular calcification in dialysis patients.
    Al Humoud H; Al-Hilali N; Ahmad AA; Ninan VT; Nampoory MR; Rizk AM; Ali JH; Johny KV
    Transplant Proc; 2005 Dec; 37(10):4183-6. PubMed ID: 16387073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease.
    Schaefer B; Schlosser K; Wühl E; Schall P; Klaus G; Schaefer F; Schmitt CP
    Nephrol Dial Transplant; 2010 Aug; 25(8):2590-5. PubMed ID: 20181803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.
    Walsh M; Manns BJ; Klarenbach S; Tonelli M; Hemmelgarn B; Culleton B
    Hemodial Int; 2010 Apr; 14(2):174-81. PubMed ID: 20041960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
    Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
    Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of causes of death in children and adolescents on chronic peritoneal dialysis and hemodialysis in 10 year period: single center experience].
    Litwin M; Grenda R; Latoszyńska J; Boguszewska-Baczkowska A; Prokurat S
    Pol Merkur Lekarski; 2000 Apr; 8(46):285-6. PubMed ID: 10897653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
    Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.